ESC 2022 | INVICTUS and PRE18FFIR

On the 3erd day of the European Cardiology Congress 2022 the INVICTUS study was presented, including 4565 patients with atrial fibrillation secondary to rheumatism driven CAD. The aim of this study was to compare the use of Rivaroxaban vs vitamin K antagonists (VKA) in this populations. Mean age was 50 and most patients were women. 

ESC 2022

Primary end point was stroke, systemic thromboembolism, AMI, or cardiovascular death. Study outcomes resulted in 560 primary end point events in the rivaroxaban group vs 446 events in the VKA group (HR 1.25; 95% CI 1.10-1.41). On individual analysis, Rivaroxaban increased the risk of death by 23% and stroke by 37%. However, there were no differences in risk of bleeding between the groups. Drug discontinuation was more frequent in the Rivaroxaban group. 

Among rivaroxaban patients, when looking at RIN valued before study kickoff, within therapeutic range, it was 33%, and at follow-up, it reached 64% in 4 years. 

The use of vitamin K antagonists should be the standard treatment for rheumatic atrial fibrillation. We need further study to properly assess the different therapies for this special population. 

On the other hand, a multicenter prospective study was presented, the PRE18FFIR, which used sodium fluoride positron emission tomography scan (PET) to identify vulnerable plaque without the need for intravascular ultrasound imaging, predicting the risk of future cardiovascular events. 704 AMI and multivessel patients were included. They all received PET and coronary CT angiography and were followed up to 2 years. 

Read also: ESC 2022 | SECURE Trial.

There were no differences between patients with active coronary microcalcification and those who did not present any. However, when looking at cardiovascular death or AMI, events rate was higher among patients with positive PET imaging for CMA. 

This study shows an important role for PET in the assessment of cardiovascular risk. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...